Nykode Therapeutics is selling for 2.83 as of the 28th of November 2024. This is a 5.20% up since the beginning of the trading day. The stock's lowest day price was 2.5. Nykode Therapeutics has hardly any chance of experiencing financial distress in the next few years, but has generated negative returns over the last 90 days. Equity ratings for Nykode Therapeutics ASA are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 30th of August 2024 and ending today, the 28th of November 2024. Click here to learn more.
Although Nykode Therapeutics' alpha and beta are two of the key measurements used to evaluate Nykode Therapeutics' performance over the market, the standard measures of volatility play an important role as well.
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Nykode Therapeutics stock to make a market-neutral strategy. Peer analysis of Nykode Therapeutics could also be used in its relative valuation, which is a method of valuing Nykode Therapeutics by comparing valuation metrics with similar companies.